AbbVie Inc (ABBV)vsCencora Inc. (COR)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
COR
Cencora Inc.
$325.37
-0.31%
HEALTHCARE · Cap: $65.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 417% more annual revenue ($332.77B vs $64.39B). ABBV leads profitability with a 9.8% profit margin vs 0.8%. ABBV appears more attractively valued with a PEG of 0.54. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
COR
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Margin of Safety
-70.4%
Fair Value
$190.32
Current Price
$325.37
$135.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 86 in profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 2.4B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Moderate valuation
0.8% margin — thin
Operating margin of 1.4%
Trading at 20.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : COR
The strongest argument for COR centers on Return on Equity, Altman Z-Score, Market Cap. PEG of 0.65 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : COR
The primary concerns for COR are P/E Ratio, Profit Margin, Operating Margin. Debt-to-equity of 3.84 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
COR carries more volatility with a beta of 0.58 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 62/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?